Royalty Report: Drugs, Cancer, Therapeutic – Collection: 27417


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology
  • Disease
  • Diagnostic Substances
  • Delivery
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27417

License Grant
We have acquired certain product/technology licenses from University.  These properties include exclusive world-wide licenses covering the composition, manufacturing and use of Avicine (a therapeutic vaccine).
License Property
Avicine, therapeutic cancer vaccine, is designed to produce an immune response against a well-characterized target, human chorionic gonadotropin (hCG). hCG is a hormone produced during pregnancy that plays a variety of roles in fostering the development of a fetus.
Field of Use
The rights granted apply in all fields of use with the exception of fertility regulation, including treating and/or preventing cancer.  Our proprietary rights also include the unrestricted use of its vaccine technology for non-hormonal cancer applications.   We enjoy the right to commercialize any new intellectual property relating to our licensed subject matter including access and use of all new experimental data resulting from research.

IPSCIO Record ID: 27095

License Grant
The University hereby grants to the Licensee a license with the right to sublicense others, under Licensed Patents and Licensed Know How to develop, test, manufacture, export, import, sell and use Subject Products and Subject Services in the Field of Use, which license, except insofar as otherwise provided herein.
License Property
Licensed Product, Licensed Vaccine and Licensed Service are Subject Product, Subject Vaccine and Subject Service, respectively, insofar as covered by the within License.
Field of Use
Field of Use shall be the use of Subject Products and Subject Service in the case of the non-hormonal antigens for the treatment, detection, diagnosis and/or prevention of cancer and in the case of hCG, for any other application except cancer (which is covered in the agreement of March 12, 1996), and except for fertility control.

IPSCIO Record ID: 27915

License Grant
The French Licensor, a cancer-research institute,  granted the Licensee French an exclusive, worldwide license under the licensed patents, which relate to monoclonal antibodies, cell lines, genetic sequences and gene-based products that target and are related to a hormone called human chorionic gonadotropin.
License Property
The licensed patents include United States patents  US 6194154 and FR9602683, and US 6514708 and FR9602683. The Licensee will have the right to grant sublicenses.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.